×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
02:30 pm
nvo
NC Community Colleges Shine in Statewide Celebration of Excellence [Yahoo! Finance]
Low
Report
NC Community Colleges Shine in Statewide Celebration of Excellence [Yahoo! Finance]
4/7
10:07 am
nvo
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes [Yahoo! Finance]
Low
Report
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes [Yahoo! Finance]
4/7
07:40 am
nvo
Obesity drugs won't be covered by Medicare under 2026 CMS policy [Yahoo! Finance]
Medium
Report
Obesity drugs won't be covered by Medicare under 2026 CMS policy [Yahoo! Finance]
4/5
01:26 am
nvo
'I've seen how weight loss can be life-changing for patients' [Yahoo! Finance]
Medium
Report
'I've seen how weight loss can be life-changing for patients' [Yahoo! Finance]
4/4
07:57 pm
nvo
Trump administration halts Biden proposal to let Medicare, Medicaid cover anti-obesity drugs [CNN]
Medium
Report
Trump administration halts Biden proposal to let Medicare, Medicaid cover anti-obesity drugs [CNN]
4/4
07:14 pm
nvo
Trump administration halts Biden proposal to let Medicare, Medicaid cover anti-obesity drugs [CNN]
Medium
Report
Trump administration halts Biden proposal to let Medicare, Medicaid cover anti-obesity drugs [CNN]
4/4
11:12 am
nvo
Trump’s Tariffs May Target Pharmaceuticals—Here’s How Drug Prices Could Change [Forbes]
Low
Report
Trump’s Tariffs May Target Pharmaceuticals—Here’s How Drug Prices Could Change [Forbes]
4/4
05:31 am
nvo
Glucagon-Like Peptide 1 Market Research Report 2025: Preference for Injectable Therapies, Clinical Efficacy, Safety Demand, & Advancements in Diabetes Research Fueling Growth - Forecast to 2034 [Yahoo! Finance]
Medium
Report
Glucagon-Like Peptide 1 Market Research Report 2025: Preference for Injectable Therapies, Clinical Efficacy, Safety Demand, & Advancements in Diabetes Research Fueling Growth - Forecast to 2034 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
06:05 am
nvo
Form 6-K NOVO NORDISK A S For: Apr 03
Low
Report
Form 6-K NOVO NORDISK A S For: Apr 03
3/31
06:02 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 27
Medium
Report
Form 6-K NOVO NORDISK A S For: Mar 27
3/10
07:58 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 10
Medium
Report
Form 6-K NOVO NORDISK A S For: Mar 10
2/27
10:59 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 27
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 27
2/10
10:09 am
nvo
Form IRANNOTICE NOVO NORDISK A S
Low
Report
Form IRANNOTICE NOVO NORDISK A S
2/7
08:27 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 07
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 07
2/6
07:37 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 06
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 06
2/5
07:18 am
nvo
Form 6-K NOVO NORDISK A S For: Dec 31
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: